Did you know that the Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis? It is a human herpes virus 4 that is usually spread among adolescents and young adults, as it is spread through body fluids, especially saliva.
Given the ease of its transmission, the QIMR Berghofer Institute for Medical Research developed a new experimental vaccine that has achieved potent and long-lasting immune protection in mice.
The dose is directed at the lymph nodeskey pieces in the operation of the body’s immune system. According to its authors, the vaccine not only produced strong antibodies and T cells to fight the WEBbut was also shown to induce a particular type of immunity to protect against virus-associated tumor growth.
“What we have done is we have engineered what we call another arm of the immune system, which we call T cells, and we combine it with antibodies, and this new formulation will induce both the antibody and T cell immune responses,” he explained in a statement Rajiv Khanna, immunologist.
How does it work? The antibodies bind to unwanted invading pathogens to remove them, while the T cells directly destroy these pathogens and help coordinate the body defenses.
The researchers are nearing the final stages of its creation. If EBV is not treated, it can lead to cancer of the throat and nose, as well as multiple sclerosis.
The research has been published in Nature.
2023-08-11 23:05:52
#Scientists #Develop #Experimental #Vaccine #Showing #Promising #Results #EpsteinBarr #Virus
